<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-00836032</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-01T21:28:42+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.</title>
            <author role="crp">
              <persName>
                <forename type="first">Sebastien</forename>
                <surname>Benzekry</surname>
              </persName>
              <email type="md5">058c3fc27bb7f758cba0c0195d61a833</email>
              <email type="domain">phare.normalesup.org</email>
              <idno type="idhal" notation="string">sebastien-benzekry</idno>
              <idno type="idhal" notation="numeric">12116</idno>
              <idno type="halauthorid" notation="string">490712-12116</idno>
              <idno type="ARXIV">https://arxiv.org/a/benzekry_s_1</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-3749-8637</idno>
              <idno type="GOOGLE SCHOLAR">https://scholar.google.fr/citations?user=xsLpdFAAAAAJ&amp;hl=fr&amp;oi=ao</idno>
              <idno type="IDREF">https://www.idref.fr/159344212</idno>
              <orgName ref="#struct-248373"/>
              <affiliation ref="#struct-225060"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Philip</forename>
                <surname>Hahnfeldt</surname>
              </persName>
              <email type="md5">6bc727329377e3eae377bddbfde611de</email>
              <email type="domain">tufts.edu</email>
              <idno type="idhal" notation="numeric">942745</idno>
              <idno type="halauthorid" notation="string">717801-942745</idno>
              <orgName ref="#struct-248373"/>
              <affiliation ref="#struct-225060"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Sebastien</forename>
                <surname>Benzekry</surname>
              </persName>
              <email type="md5">6265406c2f4b74e0106bf0ba27675c40</email>
              <email type="domain">inria.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2013-06-20 12:03:57</date>
              <date type="whenWritten">2012-04-12</date>
              <date type="whenModified">2025-09-02 11:44:13</date>
              <date type="whenReleased">2013-06-20 14:08:17</date>
              <date type="whenProduced">2013-10-21</date>
              <date type="whenEndEmbargoed">2013-06-20</date>
              <ref type="file" target="https://inria.hal.science/hal-00836032v1/document">
                <date notBefore="2013-06-20"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://inria.hal.science/hal-00836032v1/file/BenzekryHahnfeldt_optimizationMetastasesV3.pdf" id="file-836032-400317">
                <date notBefore="2013-06-20"/>
              </ref>
              <ref type="annex" subtype="other" n="0" target="https://inria.hal.science/hal-00836032v1/file/MathAppendix.pdf" id="file-836032-400316">
                <date notBefore="2013-06-20"/>
              </ref>
              <ref type="externalLink" target="http://arxiv.org/pdf/1306.4842"/>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="153845">
                <persName>
                  <forename>Sebastien</forename>
                  <surname>Benzekry</surname>
                </persName>
                <email type="md5">6265406c2f4b74e0106bf0ba27675c40</email>
                <email type="domain">inria.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-00836032</idno>
            <idno type="halUri">https://inria.hal.science/hal-00836032</idno>
            <idno type="halBibtex">benzekry:hal-00836032</idno>
            <idno type="halRefHtml">&lt;i&gt;Journal of Theoretical Biology&lt;/i&gt;, 2013, 335, pp.235-44. &lt;a target="_blank" href="https://dx.doi.org/10.1016/j.jtbi.2013.06.036"&gt;&amp;#x27E8;10.1016/j.jtbi.2013.06.036&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Journal of Theoretical Biology, 2013, 335, pp.235-44. &amp;#x27E8;10.1016/j.jtbi.2013.06.036&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-836032-400317"/><ref corresp="#file-836032-400316"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="TDS-MACS">Réseau de recherche en Théorie des Systèmes Distribués, Modélisation, Analyse et Contrôle des Systèmes</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.</title>
                <author role="crp">
                  <persName>
                    <forename type="first">Sebastien</forename>
                    <surname>Benzekry</surname>
                  </persName>
                  <email type="md5">058c3fc27bb7f758cba0c0195d61a833</email>
                  <email type="domain">phare.normalesup.org</email>
                  <idno type="idhal" notation="string">sebastien-benzekry</idno>
                  <idno type="idhal" notation="numeric">12116</idno>
                  <idno type="halauthorid" notation="string">490712-12116</idno>
                  <idno type="ARXIV">https://arxiv.org/a/benzekry_s_1</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-3749-8637</idno>
                  <idno type="GOOGLE SCHOLAR">https://scholar.google.fr/citations?user=xsLpdFAAAAAJ&amp;hl=fr&amp;oi=ao</idno>
                  <idno type="IDREF">https://www.idref.fr/159344212</idno>
                  <orgName ref="#struct-248373"/>
                  <affiliation ref="#struct-225060"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Philip</forename>
                    <surname>Hahnfeldt</surname>
                  </persName>
                  <email type="md5">6bc727329377e3eae377bddbfde611de</email>
                  <email type="domain">tufts.edu</email>
                  <idno type="idhal" notation="numeric">942745</idno>
                  <idno type="halauthorid" notation="string">717801-942745</idno>
                  <orgName ref="#struct-248373"/>
                  <affiliation ref="#struct-225060"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">16404</idno>
                <idno type="issn">0022-5193</idno>
                <idno type="eissn">1095-8541</idno>
                <title level="j">Journal of Theoretical Biology</title>
                <imprint>
                  <publisher>Elsevier</publisher>
                  <biblScope unit="volume">335</biblScope>
                  <biblScope unit="pp">235-44</biblScope>
                  <date type="datePub">2013-10-21</date>
                </imprint>
              </monogr>
              <idno type="arxiv">1306.4842</idno>
              <idno type="doi">10.1016/j.jtbi.2013.06.036</idno>
              <idno type="pubmed">23850479</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="es">Metronomics</term>
                <term xml:lang="es">Optimal control</term>
                <term xml:lang="es">Metastases</term>
                <term xml:lang="es">Cancer modeling</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv.can">Life Sciences [q-bio]/Cancer</classCode>
              <classCode scheme="halDomain" n="math.math-ap">Mathematics [math]/Analysis of PDEs [math.AP]</classCode>
              <classCode scheme="halDomain" n="math.math-oc">Mathematics [math]/Optimization and Control [math.OC]</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Although optimal control theory has been used for the theoretical study of anti-cancerous drugs scheduling optimization, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored. Here, we use a previously published model for metastatic development to define an optimal control problem at the scale of the entire organism of the patient. In silico study of the impact of different scheduling strategies for anti-angiogenic and cytotoxic agents (either in monotherapy or in combination) is performed to compare a low-dose, continuous, metronomic administration scheme with a more classical maximum tolerated dose schedule. Simulation results reveal differences between primary tumor reduction and control of metastases but overall suggest use of the metronomic protocol.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-225060" status="VALID">
          <orgName>Center of Cancer and Systems Biology</orgName>
          <orgName type="acronym">CCSB</orgName>
          <desc>
            <address>
              <addrLine>Center of Cancer Systems Biology GRI / Tufts University School of Medicine Steward St. Elizabeth's Medical Center 736 Cambridge Street, CBR building Boston, MA 02135 USA</addrLine>
              <country key="US"/>
            </address>
            <ref type="url">http://cancer-systems-biology.org/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-248373" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-248373" status="VALID">
          <idno type="IdRef">252437756</idno>
          <idno type="ROR">https://ror.org/05wvpxv85</idno>
          <orgName>Tufts University [Medford]</orgName>
          <desc>
            <address>
              <addrLine>419 Boston Ave, Medford, Massachusetts 02155</addrLine>
              <country key="US"/>
            </address>
            <ref type="url">http://www.tufts.edu/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>